13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Xetra |
94,100 |
07.08.24 14:22:48 |
+0,940 |
+1,01% |
94,020 |
94,080 |
93,560 |
93,160 |
|
REGENERON PHARMAC.DL-,001 |
881535 |
Frankfurt |
976,800 |
07.08.24 08:12:00 |
-20,800 |
-2,08% |
984,400 |
996,000 |
976,800 |
997,600 |